Mizuho Securities analyst Uy Ear maintains $Sarepta Therapeutics (SRPT.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 46.0% and a total average return of 5.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Sarepta experienced a significant third-quarter performance surpassing expectations in terms of overall and Elevidys revenue. The company's consistent guidance for Elevidys seems to err on the side of caution.
Sales of Elevidys and the exon-skipping franchise surpassed consensus expectations, and the management's outlook for Q4 Elevidys remains intact, which may set the stage for further success barring significant holiday disruptions. There's anticipation for a possible increase to the FY25 guidance come January, though current market valuations reflect a perspective that views the franchise through a five-year lens leading up to the loss of exclusivity.
Sarepta's product, Elevidys, exhibited sales growth in the third quarter that surpassed expectations, accompanied by optimistic remarks from management regarding the product's market introduction. All indications suggest that Elevidys has the potential to evolve into a product generating several billions in sales, which could be further enhanced by a series of gene therapy debuts anticipated over the forthcoming five years.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
瑞穗证券分析师Uy Ear维持$Sarepta Therapeutics (SRPT.US)$买入评级。
根据TipRanks数据显示，该分析师近一年总胜率为46.0%，总平均回报率为5.0%。
此外，综合报道，$Sarepta Therapeutics (SRPT.US)$近期主要分析师观点如下：
Sarepta在第三季度表现出色，整体和Elevidys的营业收入超出预期。该公司对Elevidys的一贯指导似乎更加谨慎。
Elevidys和exon-skipping板块的销售超出共识预期，管理层对第四季度Elevidys的展望保持完整，这可能为进一步成功打下基础，除非有重大节假日干扰。预计到一月份，可能会调高FY25的指引，尽管当前市场估值反映的观点是通过五年的视角看待该板块，在独家权利丧失之前。
Sarepta的产品Elevidys 在第三季度表现出色的销售增长，销售超出预期，管理层对产品市场推介持乐观态度。所有迹象表明，Elevidys有潜力成为一个带来几十亿美元销售额的产品，未来五年有望通过一系列基因疗法的推出进一步增强。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
